A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

PHASE2CompletedINTERVENTIONAL

Enrollment

338

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

October 26, 2022

Study Completion Date

November 3, 2022

Conditions

Cataract

Interventions

DRUG

MELT-300

Sublingual tablet

DRUG

Midazolam alone

Sublingual tablet

DRUG

Ketamine alone

Sublingual tablet

DRUG

Placebo

Sublingual tablet

Trial Locations (3)

Levenson Eye Associates, Jacksonville

Vance Thompson Vision, West Fargo

Martel Eye Medical Group, Rancho Cordova